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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has necessitated the rapid
development of antibody-based therapies and vaccines as countermeasures. Here, we use cryoelectron mi-
croscopy (cryo-EM) to characterize two protective anti-SARS-CoV-2 murine monoclonal antibodies (mAbs)
in complex with the spike protein, revealing similarities between epitopes targeted by human and murine B
cells. The more neutralizing mAb, 2B04, binds the receptor-binding motif (RBM) of the receptor-binding
domain (RBD) and competes with angiotensin-converting enzyme 2 (ACE2). By contrast, 2H04 binds adja-
cent to the RBM and does not compete for ACE2 binding. Naturally occurring sequence variants of SARS-
CoV-2 and corresponding neutralization escape variants selected in vitro map to our structurally defined
epitopes, suggesting that SARS-CoV-2 might evade therapeutic antibodies with a limited set of mutations,
underscoring the importance of combination mAb therapeutics. Finally, we show that 2B04 neutralizes
SARS-CoV-2 infection by preventing ACE2 engagement, whereas 2H04 reduces host cell attachment without
directly disrupting ACE2-RBM interactions, providing distinct inhibitory mechanisms used by RBD-specific
mAbs.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the etiologic agent of coronavirus disease 2019 (COVID-19),
is a positive-sense RNA virus in the Betacoronavirus genus. It
is closely related to other highly pathogenic coronaviruses,
most notably severe acute respiratory syndrome coronavirus
(SARS-CoV) and Middle Eastern respiratory syndrome virus
(MERS) (Zhou et al., 2020b). SARS-CoV-2 emerged in Wuhan,
China, in late 2019 (Guan et al., 2020; Zhou et al., 2020b). Since
then, it has spread to nearly every country, causing more than 39
million infections and over 1 million deaths at the time of writing
(Dong et al., 2020). Efforts to contain the spread of the virus have
been limited to social distancing, mask wearing, hand hygiene
practices, and avoidance of large gatherings, which has resulted
in widespread societal disruption and economic damage.
Numerous vaccines and therapeutics are in development
against SARS-CoV-2 infection, although currently, no prophy-
lactic countermeasures have been approved for use.
SARS-CoV-2 is a spherical, enveloped virionwith a diameter of
approximately 90 nm (Ke et al., 2020). The virion surface is deco-
rated by the spike protein, which binds to human angiotensin-
converting enzyme 2 (ACE2) on host cell surfaces, and mediates
viral entry (Hoffmann et al., 2020;Walls et al., 2020). Spikemono-
mers consist of S1 and S2 subunits, which form homotrimers
(Wrappet al., 2020). TheS1 subunit ismade upof 4 sub-domains,
S1A through S1D (Barnes et al., 2020a). S1B encodes the recep-
tor-binding domain (RBD), which directly interacts with ACE2.
The S2 subunit contains a fusion peptide, which mediates fusion
with host cell membranes after receptor binding by S1. The RBD
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is observed to have two distinct conformations, termed ‘‘up’’ and
‘‘down,’’ with the ‘‘up’’ position thought to be required for ACE2
binding.With threeS1 subunits per trimer, this leads to 4 possible
configurations for each trimeric spike protein: all down (D/D/D),
one up with two down (U/D/D), two up with one down (U/U/D),
and three up (U/U/U). In practice, themajority of spike trimers as-
sume the D/D/D and U/D/D configurations (Walls et al., 2020;
Wrapp et al., 2020), although U/U/D and U/U/U have been
observed (Barnes et al., 2020a; Ke et al., 2020).
Many neutralizing antibodies targeting SARS-CoV-2 spike
have been identified (Alsoussi et al., 2020; Barnes et al., 2020a;
Brouwer et al., 2020; Chi et al., 2020; Liu et al., 2020b; Lv et al.,
2020; Shi et al., 2020; Wang et al., 2020; Wu et al., 2020b; Zhou
et al., 2020a; Zost et al., 2020). These antibodies typically recog-
nize the RBD and function by competitively inhibiting ACE2 bind-
ing, although a subset of antibodies that display neutralizing ac-
tivity do not inhibit receptor engagement (Pinto et al., 2020; Zhou
et al., 2020a). Many antibodies targeting the receptor-binding
motif (RBM) portion of the RBD display potent neutralizing effi-
cacy in vitro, with lowng/mL IC50 (halfmaximal inhibitory concen-
tration) values (Alsoussi et al., 2020; Liu et al., 2020b; Zost et al.,
2020). Antibodies targeting alternative epitopes on spike, such as
non-RBMportions of the RBDand theN-terminal domain, gener-
ally neutralize with lower potency via unknown mechanisms.
Many anti-RBD antibodies confer protection in animal models
of SARS-CoV-2 infection, highlighting their potential use as ther-
apeutic agents (Alsoussi et al., 2020; Hassan et al., 2020).
As an RNA virus, SARS-CoV-2 can rapidly generate mutations
in critical epitopes on spike, which could render clinical interven-
tions ineffective. Indeed, a database of over 106,000 SARS-CoV-
2 sequences isolated from humans reports over 400 amino acid
substitutions in the RBD of spike alone (Singer et al., 2020). Un-
derstandingantibody responses toSARS-CoV-2at themolecular
level is critical to predicting vaccine efficacy and designing
potent, durable antibody-based therapeutics. Recently, a panel
of anti-SARS-CoV-2 antibodies was generated by immunizing
mice with recombinant RBD and boosting with SARS-CoV-2
spike trimers (Alsoussi et al., 2020). Two monoclonal antibodies
(mAbs) from this panel, 2B04 and2H04, displayedpotent neutral-
ization in vitro (IC50 of 1.46 and 154 ng/mL, respectively) and
conferred protection in vivo in a mouse model of SARS-CoV-2
infection (Alsoussi et al., 2020). Here, we use single-particle cry-
oelectronmicroscopy (cryo-EM) to characterize the epitopes tar-
geted by these antibodies. Additionally, we identify viral muta-
tions that have occurred naturally in human SARS-CoV-2
infections, which could lead to viral escape from inhibition by
these mAbs, and we probe the sensitivity of neutralization of
SARS-CoV-2 variants of concern by 2B04 and 2H04. Lastly, we
uncover a novel basis for SARS-CoV-2 neutralization by 2H04
without direct RBM blockade.
RESULTS
Anti-SARS-CoV-2 mAbs 2B04 and 2H04 bind to the RBD
of the trimeric spike protein
To understand the structural basis for binding by 2B04 and
2H04, we solved the structures of antigen-binding fragments
(Fab) of the mAbs in complex with the SARS-CoV-2 trimeric
spike protein using single-particle cryo-EM. Initial datasets
collected on standard lacey carbon grids showed a strong
top-down preferred orientation of the particles, resulting in
anisotropic maps, which prevented reliable model building. To
overcome this limitation, we collected more data with com-
plexes frozen on lacey carbon grids covered by an ultra-thin
carbon film, which showed a preferred orientation for side
views, and combined the two datasets (Figures S1A–S1D and
S2). From these data, we solved the structure of 2B04 bound
to the U/D/D conformational state of the spike protein to a res-
olution of 3.2 Å (Figures 1A and S1E). The local resolution of the





Figure 1. Anti-SARS-CoV-2 mAbs 2B04 and
2H04 bind to the RBD of the trimeric spike
(S) protein
(A) 2B04 up/down/down (U/D/D) density map. The
S1/S2 portion of the spike excluding the RBD is
colored green, with the ‘‘up’’ RBD subunit shown
in yellow. 2B04 heavy chain is shown in cyan, with
the light chain shown as pale turquoise.
(B) Map of 2B04 bound to SARS-CoV-2 trimeric
spike in the up/up/down (U/U/D) configuration,
with sections colored as in (A).
(C) 2H04 down/down/down (D/D/D) density map.
The S1/S2 region of one spike monomer excluding
the RBD is shown in green, with the RBD shown in
yellow. 2H04 heavy chain is shown in magenta,
with the light chain shown in violet.
(D) Map of 2H04 bound to SARS-CoV-2 trimeric
spike in the U/D/D configuration, colored as in (C).
Pie charts in between (A) and (B) and (C) and (D)
represent distribution of particles belonging to the
two 2B04 or two 2H04 maps, respectively. The
Fab and RBD portions of the maps are contoured
at a higher level than the core S1/S2 portions of the
map for (A)–(C).




to 8 Å at the outlying constant regions of the Fab molecule
(Figure S1G). For 2H04, the majority of the particles were in
the D/D/D conformation, allowing reconstruction with C3 sym-
metry to a resolution of 3.0 Å (Figures 1C and S1F), with local
resolution varying from 3 Å in S2 core to approximately 8 Å at
the tips of the Fabs (Figure S1H).
Both 2B04 and 2H04 were able to bind with full occupancy to
the spike protein, regardless of RBD conformation (Figures 1
and S3A–S3D). The two major RBD configurations observed
for 2B04 were U/D/D and U/U/D in roughly equal proportion,
although a minority of D/D/D particles were observed in 3D
classification (Figures 1A and 1B and S2A). For 2H04, the
majority of particles were in the D/D/D conformational state
(Figure 1C), with a smaller proportion found in a U/D/D confor-
mation (Figure 1D).
While the S1/S2 regions of the maps were well resolved, the
density at the interface between the RBD and Fab, and for the
Fab itself, was weak, presumably due to conformational flexi-
bility. To overcome this limitation, we performed a focused clas-
sification using a mask enclosing one ‘‘down’’ RBD and variable
fragment (FV) of the Fab in the case of 2B04, or all three subunits
in the case of 2H04, to identify populations of particles that had
well-ordered RBD/FV regions relative to the rest of the spike pro-
tein (Figure S2). Local non-uniform refinement of the particles
from the focused classification in cryoSPARC led to a 3.3 Å
reconstruction of the RBD/FV complex of 2B04 and a 3.14 Å
map for the RBD/FV complex of 2H04 (Figures S3E and S3F).
Importantly, the maps for the RBD and FV of both reconstruc-
tions were significantly improved, depicting continuous back-
bone traces with clear secondary structure and well-defined
density for most side chains (Figures S3G and S3H).
2B04 and 2H04 target distinct epitopes on the RBD
Using the maps generated by local refinement, we could identify
specific residues and strands at the interface of the complexes
for both mAbs. 2B04 binds to the RBM of the RBD (Figure 2A).
CDR1 and CDR2 of the heavy chain spread across the ridge
formed by the b5 and b6 strands (residues 445–454 and 491–
498, respectively) of the RBD and press up against the flexible
RBM loop (residues 472–490), while CDR-H3 mainly contacts
the RBM loop (Figure 2A). CDR1 and CDR3 of the light chain
also interact with the flexible RBM loop (Figure 2A), although
themajority of contacts derive from the heavy chain of 2B04 (Fig-
ure 2B). The total buried surface area of the complex is 656 Å2,
with 92% of the area covered by the heavy chain. For 2H04,
the epitope is formed by a discontinuous set of strands adjacent
to the RBM. 2H04 CDR-H1, CDR-H2, and CDR-H3 contact a
loop adjacent to the RBM encoded by residues 439–450 (Fig-
ure 2C). CDR-L1, CDR-L2, and CDR-L3 target the region en-




Figure 2. 2B04 and 2H04 target distinct epitopes on the RBD
(A) 2B04 targets an epitope centered on the RBM of the SARS-CoV-2 RBD. Complementarity-determining regions (CDRs) of 2B04 are shown as cartoon ribbons,
with the heavy chain colored cyan and the light chain colored pale turquoise. The RBM is shown as a transparent surface with underlying ribbon diagram.
(B) Distribution of 2B04 heavy- versus light-chain contacts on the surface of the RBD. Heavy-chain contacts colored as in (A).
(C) 2H04 targets an epitope adjacent to the RBMon the SARS-CoV-2 RBD, distal from the RBM loop. CDR regions of 2H04 are shown as cartoon ribbons, with the
heavy chain colored magenta and the light chain colored violet.
(D) Distribution of 2H04 heavy- versus light-chain contacts on the surface of the RBD. Contacts colored as in (C).
(E) Alignment of 2B04 and 2H04 models to the 2B04 RBD. 2B04 contacts are colored as in (A), and 2H04 contacts are colored as in (C). N450, the only shared
contact between 2B04 and 2H04, is colored in blue on the RBD.
(F) BLI analysis of RBD mutants to 2B04, 2H04, and ACE2. Results represent mean (±standard deviation [SD]) from two independent experiments.







Figure 3. 2B04 and 2H04 share epitopes with human antibodies
(A) Comparison of human antibodies that target the RBMof the SARS-CoV-2 RBD and 2B04. mAb groupswere formed based on overlap between their interfacial
residues as determined by Proteins, Interfaces, Structures, and Assemblies (PISA) analysis.
(B) Comparison of human antibodies that target non-RBM epitopes of the SARS-CoV-2 RBD with 2H04. Groups are based on overlap between interfacial
residues as determined by PISA analysis.
(C) Multiple sequence alignment of the SARS-CoV-2 RBD (residues 333–527) with binding footprints highlighted for human antibodies that are predicted to
compete with 2B04 or 2H04 based on structural analysis. For RBM antibodies, heavy chain, light chain, and shared contacts are shown in cyan, pale turquoise,
(legend continued on next page)




60–62 of the heavy chain also make extensive contacts with the
core fucose of the glycan on N343 (Figure S4), although it is un-
clear whether this interaction contributes to binding. Compared
with 2B04, 2H04 shows more extensive utilization of the light
chain (Figure 2D). The total buried surface area at the interface
of 2H04 and the RBD is 914 Å2, with 60% coming from the inter-
action of the heavy chain.
Alignment of the 2H04 bound RBD with the 2B04 bound RBD
showed that the Fabs have largely distinct epitope footprints,
with only one overlapping residue, N450 (Figure 2E). Binding of
2B04, but not 2H04, was significantly reduced when residues
486FNCYF490 of the RBD were mutated to 486AACAA490 (Fig-
ure 2F). By contrast, binding of 2H04, but not 2B04, to the
RBD was eliminated by mutating residues 343–346 to alanines
(Figure 2F). Alanine substitution of residues 486–490 or 500–
505 was sufficient to abrogate ACE2 binding, showing that the
2B04 epitope overlaps significantly, but not completely, with
the ACE2-binding footprint (Figure 2F). Substitution of residues
343–346 had no effect on ACE2 binding, suggesting that 2H04
might not compete with ACE2 for binding to the RBD.
2B04 and 2H04 share epitopes with human antibodies
Several groups have identified epitopes on the RBD of the
SARS-CoV-2 spike protein (Barnes et al., 2020a, 2020b; Cao
et al., 2020; Hansen et al., 2020; Hurlburt et al., 2020; Ju et al.,
2020; Liu et al., 2020a, 2020b; Lv et al., 2020; Pinto et al.,
2020; Shi et al., 2020; Wu et al., 2020a, 2020b; Yuan et al.,
2020a, 2020b; Zhou et al., 2020a). We compared the epitopes
of 2B04 and 2H04 with those of other antibodies to identify
possible conserved modes of engagement. To do this, we
aligned the structures of all available human antibody-bound
SARS-CoV-2 spike or RBD structures published in the protein
databank with our 2B04/RBD and 2H04/RBD complexes. For
the RBM antibodies, there appeared to be five distinct clusters
of epitopes on RBD (Figure 3A), and 2B04 greatly overlapped
with only one other antibody, 2-4 (Figure 3A, cyan group) (Liu
et al., 2020b). The largest group targeted the opposite side of
the RBM ridge from 2B04 and was comprised of mAbs CB6,
B38, CC12.1, CC12.3, C105, COVA2-04, and CV30 (Figure 3A,
red group) (Barnes et al., 2020a; Hurlburt et al., 2020; Shi et al.,
2020; Wu et al., 2020a, 2020b; Yuan et al., 2020b). A smaller
group adjacent to this was formed by COVA2-39 and REGN-
10933 (Figure 3A, orange) (Hansen et al., 2020; Wu et al.,
2020a). Two additional epitopes had one representative anti-
body each, made up by BD23 and P2B-2F6 (Cao et al., 2020;
Ju et al., 2020). While all of these epitopes overlap significantly
in the RBM ridge and directly block ACE2 binding, each group
also has unique interactions with the RBM (Figure 3C). All five
groups have footprints that overlap extensively with contact res-
idues between the RBD and ACE2, consistent with their ability to
neutralize SARS-CoV-2 by blocking interaction with ACE2
(Figure 3C).
For 2H04, two antibodies were identified that overlapped its
footprint: the SARS-CoV cross-reactive mAb S309 and SARS-
CoV-2-specific C135 (Figure 3B, magenta group) (Barnes
et al., 2020b; Pinto et al., 2020). Notably, the orientation of the
heavy and light chain was inverted between 2H04 and S309.
All three antibodies contact the core fucose of the glycan at
N343. Despite their overlap, each antibody also forms unique
contacts with the RBD (Figure 3C). Epitope alignment shows
that S309 makes more extensive contacts with the N terminus
of the RBD as well as the b1 strand (residues 353–358), whereas
2H04 makes unique contacts with N448, N450, and P499 (Fig-
ure 3C). In contrast to both 2H04 and S309, C135 displays fewer
contacts overall to the RBD, but makes a number of unique con-
tacts: W436, N437, and S438 (Barnes et al., 2020b). Twelve of 19
and 9 of 20 contact residues are strictly conserved between
SARS-CoV-2 and SARS-CoV spike for 2H04 and 2B04, respec-
tively, suggesting these mAbs might cross-react to SARS-CoV.
Quantitative binding analysis by BLI showed weak binding to
SARS-CoV by 2H04, with a KD of 1417 nM and half-life of
0.43min; 2B04 did not bind to SARS-CoV RBD at the tested con-
centrations (Figures S5C and S5D) (Alsoussi et al., 2020).
Proximal to the 2H04/S309 epitope are four additional groups
of antibodies. Immediately adjacent and partially overlapping
with the 2H04/S309 epitope is REGN-10987 (Figure 3B, blue
group) (Hansen et al., 2020). Further rotated away from 2H04
and REGN-10987 are three groups targeting similar yet distinct
epitopes, bound by H014 (Figure 3B, light blue group) (Lv
et al., 2020), COVA1-16 (Figure 3B, dark green group) (Liu
et al., 2020a), and CR3022 or EY6A (Figure 3B, light green group)
(Yuan et al., 2020a; Zhou et al., 2020a), respectively.
Overall, the RBD appears to be highly immunogenic with a
multitude of epitopes that cluster roughly into three distinct
groups. Antibodies targeting the RBM ridge and loop are differ-
entiated by their orientation of binding on the ridge, but share a
common mechanism of action and tend to display potent
neutralization. Antibodies targeting RBM-adjacent (i.e., 2H04,
S309, REGN-10987, H014, and C135) or RBM-distal (i.e.,
COVA1-16, CR3022, and EY6A) epitopes are differentiated by
their rotation about the core RBD beta sheet and show less
potent neutralization than RBM antibodies, typically via non-
ACE2-competitive mechanisms.
SARS-CoV-2 can escape neutralization by both 2B04
and 2H04
Escape from antibody-mediated neutralization bymutation of key
binding residues is a feature of RNA viruses that hinders therapeu-
tic development. A wide variety of amino acid substitutions in the
spike protein of SARS-CoV-2have beenobserved in human infec-
tions, suggesting that SARS-CoV-2 might be able to escape anti-
body-mediated neutralization. Escapemutations generated using
a SARS-CoV-2 chimeric vesicular stomatitis virus (VSV-SARS-
CoV-2) (Case et al., 2020) under selection pressure from 2B04
and blue, respectively. For non-RBM antibodies, heavy chain, light chain, and shared contacts are shown in magenta, pale violet, and fuchsia, respectively.
SARS-CoV RBD is shown at the bottom,with substitutions relative to SARS-CoV-2 RBD highlighted in green. SARS-CoV-2 RBD contacts with ACE2 are identified
by stars at the bottom of the alignment, based on Lan et al. (2020). Escapemutants contacts are shown above the alignment as cyan circles for 2B04 andmagenta
triangles for 2H04, with the N343 glycan demarcated by a magenta diamond. Secondary structure annotation is based on the locally refined 2B04/RBD model.




and 2H04 revealed mutations at T345, R346, L441, K444, E484,
and F486 (Figure 4A) (Liu et al., 2021). Interrogation of human-
derived SARS-CoV-2 sequences in the global initiative on sharing
all influenzadata (GISAID) databaseviaCOV-GLUE revealednatu-
rally occurring variantswith substitutions at identical residues (Fig-
ure 4B; Table 1) (Shu and McCauley, 2017; Singer et al., 2020).
T345, R346, L441, and K444 lie outside the binding site for ACE2
(Figure 4C) and are all contained within the epitope for 2H04 (Fig-
ure 4D),whereasE484andF486 lie in the2B04 footprint,withF486
also acting as an ACE2 contact residue (Figures 4E and 4F).
Although these variants currently are present at low frequency in
human populations (Figure 4B), these results suggest that SARS-
CoV-2 can generate resistance to 2B04, 2H04, and other
antibodies when used as monotherapies, which could result in
expansion of resistant strains under prolonged selection pressure.
Neutralization of SARS-CoV-2 variants by 2B04 and
2H04
Several novel strains of SARS-CoV-2 bearing mutations in the
RBD have emerged since late 2020, some of which contain sub-
stitutions at E484, suggesting that these strains may not be as
sensitive to neutralization by 2B04 and 2H04 (Figure 5B). To
address this, we tested neutralization of these variant strains
by 2B04 and 2H04. In line with results from aforementioned
escape mutant studies, variants containing substitutions at
E484 (B.1.351, B.1.1.28, B.1.617.1, and B.1.526 E484K) dis-
played significantly decreasedneutralizationby2B04 (Figure 5A).
2H04 also displayed decreased neutralization potency against
certain variants, particularly those bearing the N501Y substitu-
tion (B.1.1.7, B.1.351, and B.1.1.28), but to a lesser extent than
2B04 (Figure 5A). Additionally, 2H04 was less able to neutralize
B.1.1.298 and B.1.222, bearing the Y453R and N439K muta-
tions, respectively. A cocktail of 2B04 and 2H04 was generally
able to rescue neutralization against variants that displayed
resistance to either 2B04 or 2H04 individually, although variants
containing both E484 and N501 substitutions (most notably
B.1.1.28) still displayed significantly reduced neutralization
compared with wild-type (WT) strains.
Mechanism of SARS-CoV-2 neutralization by 2B04 and
2H04
Based on our structural analysis and previous reports, 2B04
potently neutralizes SARS-CoV-2 by blocking ACE2 binding,
while 2H04 neutralizes less potently without blocking ACE2 (Fig-
ures 6A and 6B). To begin to understand why 2H04 is less effi-
cient at neutralizing SARS2-CoV-2 than 2B04, we measured
the binding affinities of these two mAbs to recombinant RBD ex-
pressed in Escherichia coli by biolayer interferometry (BLI). 2B04
tightly bound RBD with a kinetic KD value of 1.05 nM and a rela-
tively slow dissociation rate (half-life of 23.70 min) (Figure 6C).
While 2H04 bound RBD strongly, it displayed weaker affinity
(KD of 40.1 nM) and a faster off rate (half-life of 1.27 min) than
2B04 (Figure 6D). Since 2H04 recognizes the glycan of residue
N343 (Figure S4), we also assessed the binding of these two
mAbs to RBD expressed in mammalian cells (Figures S5A and
S5B). Both mAbs showed comparable affinities and kinetics to
recombinant RBDs derived from either Expi293 cells (mamma-
lian, (+)-glycosylation) or E. coli (bacterial, no glycosylation), sug-
gesting that the glycans on the RBD do not contribute to the




Figure 4. SARS-CoV-2 can escape neutralization by 2B04 and 2H04
(A) Logo plot depicting escape mutants generated by selection pressure from 2B04 or 2H04 using a chimeric VSV expressing SARS-CoV-2 spike.
(B) Identity and frequency of mutations seen in clinical isolates of SARS-CoV-2 at identical positions as the VSV-SARS-CoV-2 escape mutants. The right axis
shows the number of total sequences with mutations at each residue position, out of a total 106,606 sequences. Logo plots were generated using dmslogo
(Bloom lab).
(C) RBD with ACE2 contacts colored in green, and 2H04 escape mutants colored in magenta.
(D) Ribbon diagram showing escape mutants at the binding interface of 2H04 on the RBD.
(E) RBD with ACE2 contacts colored in green, and 2B04 escape mutants colored in cyan.
(F) Ribbon diagram showing escape mutants at the binding interface of 2B04 on the RBD.




Table 1. SARS-CoV-2 isolates with mutations at 2B04 and 2H04 escape residues
Viral protein Replacement
No. of
sequences Virus name GISAID ID Collection date
Spike T345S 1 hCoV-19/USA/WA-S1049/2020 EPI_ISL_463539 03/05/2020




R346T 2 hCoV-19/India/GJ-GBRC-380b/2020 EPI_ISL_524740 06/18/20
hCoV-19/India/GJ-GBRC333/2020 EPI_ISL_512069 07/07/20
L441I 1 hCoV-19/USA/FL-BPHL-0297/2020 EPI_ISL_480948 05/16/2020












E484* 2 hCoV-19/England/NORW-EA01B/2020 EPI_ISL_448386 04/30/2020
hCoV-19/Australia/VIC1221/2020 EPI_ISL_430518 04/01/2020
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To investigate the neutralization mechanisms of 2B04 and
2H04, we performed a BLI-based competition binding assay.
When 2B04 was immobilized, the binding of ACE2 to captured
RBD was abrogated (Figure 6E), consistent with our structural
predictions (Figure 6A). By contrast, 2H04 failed to block ACE2
binding, suggesting it might neutralize SARS-CoV-2 in a non-
ACE2-competitive manner, also in agreement with our structural
predictions (Figure 6B). Additionally, 2B04 and 2H04 were able
to bind RBD simultaneously, supporting our structural observa-
tions that 2B04 and 2H04 recognize spatially distinct epitopes
(Figures 2E and 6A and 6B).
We next performed pre- and post-attachment neutralization
assays using a GFP-expressing replication-competent VSV-
SARS-CoV-2 chimeric virus on Vero E6-TMPRSS2 cells (Case
et al., 2020). 2B04 and 2H04 were incubated with VSV-SARS-
CoV-2 before or after virus adsorption to the cell surface, and
infection was monitored 8 h post-infection by flow cytometry.
2B04 efficiently inhibited VSV-SARS-CoV-2 infection when
mixed with the virus before or after cell attachment (Figure 6F).
2H04, which did not compete with ACE2 for the binding of
RBD (Figure 6E), neutralized infection more efficiently when
added before virus attachment to cells. Thus, 2H04 likely affects
viral attachment to these target cells (Figure 6F).
To further explore how 2H04 neutralizes SARS-CoV-2, we
used quantitative real-time PCR to perform a cellular attachment
inhibition assay with authentic SARS-CoV-2 on Vero E6-
TMPRSS2 cells. As expected, 2B04 prevented SARS-CoV-2
attachment compared with the control mAb (hE16), which
agrees with our ACE2 competition binding results and indicates
that 2B04 interferes with viral engagement to cellular ACE2. Un-
expectedly, 2H04 showed comparable attachment inhibition
ability as 2B04 (Figure 6G), suggesting that 2H04 limits viral
infection by blocking interaction with non-ACE2 attachment fac-
tors on cell surfaces, or possibly by sterically blocking the virion
from close contact with host cells, thus inhibiting ACE2
engagement.
Recent studies have suggested that some neutralizing anti-
bodies inhibit SARS-CoV-2 infection more potently than their
monovalent Fab derivatives (Barnes et al., 2020b; Hansen
et al., 2020; Liu et al., 2020a). To understand whether 2B04
or 2H04 also utilize avidity to neutralize SARS-CoV-2, we
tested their potency in both bivalent and monovalent formats
against chimeric VSV-SARS-CoV-2. Both 2B04 and 2H04
Fabs still showed inhibitory activity against VSV-SARS-CoV-
2, with an 50- and 560-fold decrease in neutralization po-
tency compared with intact 2B04 and 2H04 immunoglobulin
Gs (IgGs), respectively (Figure S6). These data suggest that
bivalent 2B04 and 2H04 IgG inhibit virus infection more effec-
tively than their Fab derivatives.
DISCUSSION
We have shown that two potently neutralizing mouse antibodies
target distinct epitopes on the SARS-CoV-2 RBD, with one
engaging the RBM and another binding nearby. Notably, both
2B04 and 2H04 target epitopes shared by human mAbs (i.e.,
2-4 for 2B04 and S309 for 2H04). This suggests that these epi-
topes are immunogenic in both humans and mice and highlights
the possibility of raising therapeutic antibodies in animals.
It was noted recently that certain antibodies targeting the RBM
epitope, such asCC12.1 andB38, preferentially utilize the human
IgHV3-53 heavy-chain gene and display relatively little somatic
hypermutation (Yuan et al., 2020b). CC12.1 showed only 4 so-
matic mutations, whereas CC12.3 showed 3 substitutions and
a deletion compared with its germline precursor (Yuan et al.,
2020b). IgBLAST analysis of 2B04 shows a similarly low number
of somatic mutations, with only 3 amino acid substitutions in the
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contrast, 2H04 showed 6 heavy-chain mutations and 5 light-
chain mutations (Figures S7C and S7D). Interestingly, despite
bearing half as many somatic mutations as 2H04, 2B04 displays
approximately 40-fold higher binding affinity for SARS-CoV-2
RBD (Figures 6C and 6D). Also notable is the conservation of par-
atope contact residues in 2B04. Only 2 of 15 contact residues in
the heavy chainweremutated,with oneof the twobearing a func-
tionally conservative S31Nmutation. Seven of these contact res-
idues also were identical in the human IgHV3-53 gene, with a
further 6 bearing conservative substitutions. Only two residues
in 2B04 were completely non-conserved compared with human
IgHV3-53, I30, and N58 (S30 and Y58 in IgHV3-53). Like IgHV3-
53-derived antibodies in humans, the epitope targeted by 2B04
also appears tobe relatively immunodominant inmice, as clonally
A
B
Figure 5. Neutralization of SARS-CoV-2
variants by 2B04 and 2H04
(A) Neutralization curves of SARS-CoV-2 variants
of concern by 2B04 or 2H04 individually and in
combination. Data are mean of 2 independent
experiments. Inset table summarizes chimeric vi-
ruses and variants of concern used.
(B) Structural depiction of the SARS-CoV-2 RBD
shown as a silver surface with 2B04 and 2H04
shown as ribbon diagrams and colored cyan/pale
turquoise and magenta/violet for heavy and light
chains, respectively. Residues substituted in var-
iants of concern are shaded orange, with lineages
for each variant listed below the substitution and
colored as in (A).
and functionally similar antibodies have
been identified (Alsoussi et al., 2020; Has-
san et al., 2020).
One notable feature of 2B04 is its ability
to bind RBD subunits in both the ‘‘up’’ and
‘‘down’’ conformations (Figures1Aand1B
and 6H). mAb 2-4 was only reported to
bind ‘‘down’’ RBDs, whereas antibodies
targeting the opposite flank of the RBM,
such as CC12.1, only bind to RBD in the
‘‘up’’ conformation (Barnes et al., 2020a;
Liu et al., 2020b; Wu et al., 2020a; Yuan
et al., 2020b). Notably, the antibody
BD23 was observed to bind only one
‘‘down’’ RBD per trimer (Cao et al.,
2020), suggesting that binding orientation
on the RBM ridge modulates antibody-
binding stoichiometry to SARS-CoV-2
spike trimers.Because antibodies in these
groups tend to display low ng/mL IC50
values, more studies are needed to deter-
mine whether differential binding stoichi-
ometry has functional consequence. It is
worth noting, however, that 2B04 appears
to be the most potently neutralizing anti-
body covered in our analysis (IC50 of
1.47ng/mL against authentic virus). Addi-
tionally, a few other RBM antibodies that
have been shown to bind both ‘‘up’’ and ‘‘down’’ RBDs, such as
COVA2-15 and C144, display similarly potent neutralization (IC50
of 9 ng/mL against authentic virus for COVA2-15; IC50 of
2.55 ng/mL against authentic virus for C144) (Brouwer et al.,
2020; Robbiani et al., 2020).
Several potently neutralizing mAbs inhibit SARS-CoV-2 infec-
tion through unknown mechanisms. Non-RBD mAbs 4A8 and
COVA1-21 potently neutralize SARS-CoV-2 infection in vitro
(Brouwer et al., 2020; Chi et al., 2020). S309 and 47D11 are
mAbs that bind RBD, but cannot block spike binding to ACE2
(Pinto et al., 2020; Wang et al., 2020). We have shown that
although 2H04 does not block ACE2 binding to the isolated
RBD, it still impedes virus attachment as efficiently as the
ACE2-blocking mAb 2B04, and unlike 2B04, loses much of its








Figure 6. Mechanism of SARS-CoV-2 neutralization by 2B04 and 2H04
(A) Structural alignment of 2B04/RBD with ACE2/RBD complex (PDB: 6M0J). RBD is displayed as a surface model colored in gray. 2B04 is colored in cyan, and
ACE2 is colored in green.
(B) Structural alignment of 2H04/RBD with ACE2/RBD complex (PDB: 6M0J). RBD is colored in gray, 2H04 is colored in magenta, and ACE2 is colored green.
(C and D) Binding affinity of 2B04 (C) and 2H04 (D) for SARS-CoV-2 RBD to bacterially derived SARS-CoV-2 RBD. The kinetic values were fitted to a 1:1 Langmuir
binding model (KD, kinetic). Steady-state analysis is shown on bottom (KD, equilibrium), with inset Scatchard plots. The data were analyzed using Biaevaluation
3.1 (GE Healthcare) with a single representative sensogram of two independent experiments shown for each mAb.
(E) BLI traces of competitive binding of 2B04, 2H04, and ACE2 against SARS-CoV-2 RBD. mAbs were loaded onto anti-human IgG Fc biosensors, and re-
combinant RBD was captured, followed by either 2H04 Fab, 2B04 Fab, or monomeric human ACE2 (hACE2).
(F) Pre- and post-attachment inhibition assays. Serial dilutions of mAbswere either pre-incubated with GFP expressing VSV-SARS-CoV-2 followed by addition of
mAb-virusmixture to Vero E6-TMPRSS2 cells (pre-attachment), or themAbswere added to the cells after viral attachment (post-attachment). GFP+ infected cells
were measured by flow cytometry 8 h post-infection. Experiments were performed two independent times in triplicate. Error bars indicate mean ± SEM.
(G) Attachment blockade assay with authentic SARS-CoV-2. The fold change of viral RNA on cell surfaces was measured by quantitative real-time PCR and
compared with control cells infected with untreated virus. hE16 (anti-West Nile virus) was used as an isotype control.
(H) Cartoon depicting different SARS-CoV-2 spike configurations. Spike trimers with three RBDs in the ‘‘down’’ configuration cannot bind ACE2, whereas spike
configurations with at least one RBD in the ‘‘up’’ configuration can bind ACE2.
(I) Cartoon model of SARS-CoV-2 neutralization by 2B04 and 2H04. 2H04 binds to SARS-CoV-2 virions and inhibits viral accumulation at cellular surfaces,
possibly by preventing heparan sulfate or other attachment factors from interacting with the RBD. 2B04 neutralizes by binding to the RBM, directly preventing
RBD binding to ACE2, which is required for cellular entry. Data in (G) are the mean of three independent experiments performed in duplicate. Error bars indicate
SD. Statistical significance was determined by two-way ANOVA. ns, not significant; *p < 0.05; ***p < 0.001; ****p < 0.0001.




potency against virions already attached to host cells. These
data indicate there may be alternative attachment receptor(s)
in addition to ACE2 that 2H04 is blocking. Indeed, heparan sul-
fates and C-type lectins (DC-SIGN or L-SIGN) may have roles
in SARS-CoV-2 infection and transmission (Amraie et al., 2020;
Bermejo-Jambrina et al., 2020; Clausen et al., 2020; Partridge
et al., 2020). Thus, we speculate that 2H04 might neutralize
SARS-CoV-2 by inhibiting viral binding to target cell surfaces
via unknown receptors or attachment factors. Importantly, these
experiments do not exclude the possibility that 2H04 can block
the trimeric spike binding ACE2 by selecting a particular spike
conformation or otherwise sterically preventing dimeric ACE2
engagement (Barnes et al., 2020b; Huo et al., 2020; Liu et al.,
2020a). Further studies are required to delineate which of these
possibilities plays a dominant role in neutralization.
An antibody identified in a SARS-CoV patient from 2003, mAb
S309, was shown to cross-neutralize SARS-CoV-2 (Pinto et al.,
2020). Both S309 and 2H04 target an overlapping RBM-adjacent
epitope with a relatively high degree of conservation of contact
residues betweenSARS-CoVandSARS-CoV-2.Both antibodies,
as well as the SARS-CoV-2-specific C135 (Barnes et al., 2020b),
also neutralize SARS-CoV-2 without blocking ACE2 binding. As
2H04 neutralizes SARS-CoV-2 by reducing cellular attachment
without blocking ACE2 engagement, we predict that S309 and
C135 also inhibit SARS-CoV-2 infection through a similar mecha-
nism. Although 2H04 exhibits relatively low-affinity binding to
SARS-CoV RBD, it may be possible to enhance the affinity of
2H04 for SARS-CoV RBD by structure-guided mutagenesis,
thus enhancing cross-neutralization of 2H04, enabling its poten-
tial use as a dual therapeutic option for both SARS-CoV and
SARS-CoV-2.
The facts that VSV expressing the SARS-CoV-2 spike can
escape antibody-mediated neutralization and that mutations at
identical residues have been observed in naturally occurring
SARS-CoV-2 variants suggest that SARS-CoV-2 might escape
antibody-mediated neutralization when used as monotherapy.
In linewith these predictions, variants of SARS-CoV-2 containing
RBD mutations that disrupt neutralization by RBM-targeting an-
tibodies, including 2B04 and 2H04, and convalescent and
vaccinee serum-derived polyclonal antibodies, have recently
emerged (Figure 5) (Chen et al., 2021; Garcia-Beltran et al.,
2021; Wang et al., 2021a, 2021b). K417, E484, and N501 are
substituted in multiple variants of concern and are contact resi-
dues for a variety of previously described RBM-targeted anti-
bodies, particularly those utilizing the IgHV3-53 germline
sequence (Figures 3C, 5, and S7). Notably, the epitopes targeted
by REGN-10933 and REGN-10987, which comprise the REGN-
COV2 therapeutic, encompass contacts that are subtituted in
these variants (K417, E484, and N501 for REGN-10933; N501
for REGN-10987) (Figure 3C). Although REGN-10933 displays
less neutralizing potency against B.1.351, in combination with
REGN-10987 it retains most of its neutralizing efficacy (Tada
et al., 2021; Wang et al., 2021a). The emergence and spread of
neutralization-resistant variants highlights the ongoing threat of
resistance, underscoring the need for continued development
of next generation therapeutic antibody cocktails.
Overall, we report high-resolution cryo-EM structures of two
anti-SARS-CoV-2 neutralizing antibodies that bind to the RBD
portion of the spike protein. These antibodies target distinct
epitopes and act through disparate mechanisms of action
(Figure 6I). These findings advance our understanding of the
epitopes targeted by multiple species of vertebrate when
challenged with SARS-CoV-2 and highlight two candidate anti-
bodies that can be used together, and in conjunction with other
antibodies, for the prevention or treatment of SARS-CoV-2
infection.
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map
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map
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Data and code availability
d Density maps used to build models were deposited in the EMDBwith the following accession numbers: 2B04 U/D/D as EMDB:
EMD-22748, 2B04/RBD locally refined as EMDB: EMD-22749, 2H04 D/D/D as EMDB: EMD-22750, and 2H04/RBD locally
refined as EMDB: EMD-22751. Models built with these maps were deposited in the PDB with the following accession codes:
2B04 U/D/D as PDB: 7K9H, 2B04/RBD locally refined as PDB: 7K9I, 2H04 D/D/D as PDB: 7K9J, and 2H04/RBD locally refined
as PDB: 7K9K. Additional maps of 2B04 U/U/D and 2H04 U/D/D were deposited in the EMDB with the following accession
numbers: 2B04 U/U/D as EMDB: EMD-22752, and 2H04 U/D/D as EMDB: EMD-22753.
d This paper does not report original code.
d Any additional information required to reanalayze the data reported in this paper is available from the lead contact upon
request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
Vero cells were cultured at 37C in DMEM supplemented with 10% FBS. Expi293 cells were cultured in Expi293 serum-free media at
37C in an 8% CO2 atmosphere.
Viruses
SARS-CoV-2 (2019 n-CoV/USA_WA1/2020) was obtained from the Centers for Disease Control and amplified in Vero CCL81 cells.
Chimeric VSV-SARS-CoV-2 stocks were generated as previously described (Case et al., 2020). The chimeric virus was amplified on
MA104 cells, and neutralization assays were performed on Vero-E6-TMPRSS2 cells. SARS-CoV-2 variants viruses were amplified on
Vero-E6-TMPRSS2 cells as previously described (Chen et al., 2021; VanBlargan et al., 2021).
Recombinant proteins
Recombinant mammalian-derived SARS-CoV-2 spike protein RBD was produced in Expi293 cells grown in a 37C 8% CO2 atmo-
sphere humidified shaker incubator. Bacterially-derived SARS-CoV-2 RBD was produced in E. coli BL21(DE3) cells grown in liquid
culture at 37C in a shaker incubator.
METHOD DETAILS
Protein production and purification
Genes encoding SARS-CoV-2-spike (residues 1-1213, GenBank: MN908947.3) and RBD (residues 319-541) were cloned into a
mammalian expression vector with a C-terminal hexahistidine tag. For spike, 986KV987 wasmutated to 986PP987, S1/S2 furin cleavage
sites were disrupted to stabilize the prefusion conformation, and a C-terminal foldon trimerization motif was incorporated. The vec-
tors were transiently transfected into Expi293F cells with ExpiFectamine, and recombinant spike andRBDproteinswere purified from
culture supernatants using cobalt-charged resin (G-Biosciences). In some cases, size exclusion chromatography was used for addi-
tional purification (superose 6 increase for spike, and superdex 75 for RBD).
Untagged RBD was expressed in E. coli BL21(DE3) cells and oxidatively refolded from inclusion bodies as previously
described (Oliphant et al., 2007). RBD variants were made using a Q5 Site-Directed Mutagenesis Kit (NEB), and were expressed
and purified as described for WT RBD. Genes encoding human ACE2 (hACE2 residues 1-615) were synthesized (IDT) and
placed into a mammalian expression vector with a C-terminal HRV-3C protease cleavage site and a human Fc fragment, as
previously reported (Case et al., 2020). The vector was transfected into Expi293F cells using FectoPRO (Poly-plus) and
hACE2-hFc was purified from culture supernatants 4 days post transfection by affinity chromatography using protein A resin
(GoldBio). Monomeric hACE2 was generated by incubating hACE2-hFc with HRV-3C protease overnight at 4C. hACE2 was
subsequently purified by passage over a protein A column to remove cleaved Fc and further purified through size exclusion
chromatography.
Cryo-EM sample preparation
For standard lacey carbon grid (Ted Pella #01895-F) datasets, trimeric SARS-CoV-2 spike at a concentration of 1 mg/mL in 20 mM
HEPES pH 7.5, 150 mM NaCl was combined with 1 molar equivalent of a papain-cleaved Fab form of either 2B04 or 2H04 in 20 mM
HEPES pH 7.5, 150 mM NaCl, and incubated for 10 minutes before flash-freezing on lacey carbon grids using a Vitrobot Mk IV
(ThermoFisher Scientific). For lacey carbon grids with ultra-thin carbon film (Ted Pella #01824G), SARS-CoV-2 spike was diluted
to 0.2 mg/mL prior to mixing with 1 molar equivalent of either 2B04 or 2H04 Fab and then vitrified on thin-film lacey carbon grids
using a Vitrobot Mk IV (ThermoFisher Scientific). Both sets of grids were glow discharged prior to sample application in a GloQube
(EMS) for at least 20 s under vacuum.





Frozen grids were transferred to a Cs-corrected FEI Titan Krios 300KV microscope equipped with a Gatan K2 Summit detector
mounted on a BioQuantum 968 energy filter operating in zero lossmode with a slit width of 20 eV. Movies were collected at a nominal
magnification of 105,000X resulting in a pixel size of 1.1 Å/pixel, with 45 frames per movie at 200ms each with a dose of 1.49 e-/Å2/
frame, resulting in a total dose of 66.9 e-/Å2/movie.
Cryo-EM data processing
Raw movies for both datasets were motion corrected using MotionCor2 v1.3.1 (Zheng et al., 2017). Micrograph contrast transfer
function correction parameters were estimated using GCTF v1.06 (Zhang, 2016). Particles were picked on each dataset using CrY-
OLO v1.7.1 employing a general model (Wagner et al., 2019). Particles were first subjected to 2D classification in relion 3.1 (Scheres,
2012; Zivanov et al., 2018). Good 2D classes from both holey lacey carbon and thin-film lacey carbon particle sets were picked and
merged for both 2B04 and 2H04. The merged particle datasets were then subjected to 3D classification using a 7.5 degree angular
search for 25 iterations followed by 25 iterations of local searches at 1.8 degree sampling to separate spike conformational states, as
previously described (Walls et al., 2020). Particles for each conformational state were put through CTF refinement and Bayesian
polishing in relion 3.1 (Zivanov et al., 2019) prior to non-uniform refinement in cryoSPARC v2.15 to generate the final full-spike
maps (Punjani et al., 2017). To enhance resolution and map quality at the Fab/RBD interface, masks encompassing either one FV
and RBDof the U/D/D 2B04 dataset or all three FV and RBDpositions for the D/D/D 2H04 dataset were used for focused classification
on their respective particle sets in relion 3.1. Classes with well-resolved detail in the masked region were selected, and the particles
expanded with C3 symmetry. Finally, the particles were subjected to local non-uniform refinement in cryoSPARC v2.15 using a mask
encompassing one FV/RBD for both 2B04 and 2H04 to generate the locally refined maps.
Model building
For the locally refined maps, an initial model was generated by using protein BLAST with the Fab sequences to identify pre-existing
Fab models that displayed high sequence similarity to 2B04 (PDB: 1GIG) and 2H04 (PDB: 6DG2 for heavy chain, PDB: 1K4C for light
chain). The initial model for the RBD for 2B04 was taken from the crystal structure of Fab CR3022 bound to SARS-CoV-2 RBD (PDB
6W41), while for 2H04 it was derived from the cryo-EM structure of SARS-CoV-2 spike (PDB 6VXX). All starting model components
were combined and rigid body fit into their respective maps. Model building and refinement were performed with Coot 0.91 (Emsley
et al., 2010), Isolde v0.93 (Croll, 2018), and phenix (Adams et al., 2010). Initial models for the full spike/Fab complex structures were
generated by combining the locally-refined structures of 2B04 and 2H04 with previously solved cryo-EM structures of SARS-CoV-2
spike proteins in the proper conformational configurations (PDB 6VYB for 2B04 U/D/D, PDB 6VXX for 2H04 D/D/D). These models
were refined subsequently using Coot 0.91, Isolde v0.93, and Phenix. Contact residues at the interfaces of the locally refined models
were identified using qtPISA to generate epitope footprints. Buried surface areas were calculated in UCSF ChimeraX with a probe
radius of 1.4 Å. Structures were visualized using UCSF ChimeraX (Goddard et al., 2018).
Binding analysis via biolayer interferometry (BLI)
Biolayer interferometry (BLI) was used to investigate the binding capacity of mAbs to wild-type or mutant RBDs on an Octet-Red96
device (ForteBio). 10 mg/mL of 2B04, 2H04 or 20 mg/mL ACE2-hFc were immobilized onto anti-human IgG Fc biosensors (ForteBio)
for 3minutes. After a 30 swash, the pinswere dipped into running buffer (10mMHEPES, 150mMNaCl, 3mMEDTA, and 0.005%P20
surfactant with 3% BSA) containing 500 nM recombinant RBDs (RBD343-346, RBD486-490, RBD500-505 and RBDWT, respec-
tively) to measure association, followed by a dissociation step in running buffer alone. The BLI traces were recorded and the
maximum binding signals were averaged at steady state and analyzed with Prism (Version 8.0).
Competition-binding analysis through BLI
Anti-human IgG Fc biosensors were loaded with 2B04 or 2H04 IgG (10 mg/mL), with a parallel control of buffer alone to monitor non-
specific binding. After a 30 s wash, the sensors were immersed into RBD-containing wells for 1 minute to capture RBD molecules,
followed by immersion into buffer containing either 2H04 Fab, 2B04 Fab, or monomeric ACE2 for 1 minute, with binding curves re-
corded in real time. The two tested subunits were considered competitive if no increase in BLI signal was observed.
Pre- and post- attachment neutralization assay
For the pre-attachment assay, serially diluted 2B04 or 2H04 were incubated with GFP expressing chimeric VSV-SARS-CoV-2 for 1
hour at 4C. The virus-mAb mixture was subsequently added to pre-cooled Vero E6-TMPRSS2 cells and incubated for 1 hour. Cells
were washed three times with cold DMEM to remove unbound virus, and the plates were transferred to a 37C incubator with 5%
CO2. 8 hours post-infection, the cells were trypsinized (Trypsin-EDTA) and fixed with 4% paraformaldehyde. Infection frequency
was quantified by measuring the number of GFP-positive infected cells via flow cytometry. For the post-attachment assay, the virus
was first incubated with chilled cells at 4C. One hour later, cells were washed with cold media to remove unbound virus, followed by
addition of serial dilutions of 2B04 or 2H04 and incubation for 1 hour at 4C. Viral infection was quantified as described above. Rela-
tive infectionwas calculated by comparing cells infectedwithmAb-bound virus to cells infectedwith untreated virus. IC50 valueswere
determined by non-linear regression with values constrained between 0 and 100. During this experiment, we observed a viral fraction




that resisted neutralization by 2H04; similar findings have been reported for other viruses (i.e., alphaviruses and flaviviruses) (Earnest
et al., 2019; Nelson et al., 2008)
Attachment blockade assay
Vero E6-TMPRSS2 cells (23 105) were seeded in 24-well plates and incubated at 37C for 24 hours. DilutedmAbs (2B04 or 2H04)were
premixedwith SARS-CoV-2 (MOI of 0.01) and incubated for 1 hour at 4C, followed by addition of themAb-virusmixture to chilled Vero
E6-TMPRSS2 cells for 1 hour at 4C. Virus alone and a control antibody (humanized anti-West Nile virus mAb, hE16) (Oliphant et al.,
2005) were included. Cells were then rinsed 4 times with chilled DMEM and once with PBS on ice before total cellular RNA extraction
usingaMagMAXmirVanaTotalRNA IsolationKit (A27828).ViralRNA levelsweremeasuredbyqRT-PCRonanABI7500Real Time-PCR
system (AppliedBiosystems) andnormalized toan internalGAPDHcontrol. The followingprimers andprobeswereused:SARS-CoV-2-
Fwd, 50-ATGCTGCAATCGTGCTACAA-30; SARS-CoV-2-Rev, 50-GACTGCCGCCTCTGCTC-30; Probe SARS-CoV-2-P, /56-FAM/
TCAAGGAACAACATTGCCAA/3BHQ_1/; GAPDH-Fwd, 59-TGTAGTTGA GGTCAATGAAGGG-39; GAPDH-Rev, 59-ACATCGCTCA
GACAC CATG-39; Probe GAPDH, 56-FAM/AAGGTCGGA/ZEN/GTCAAC GGATTTGGTC/3IABkFQ.
SARS-CoV-2 variant neutralization assays
Variant focus reduction neutralization assays were conducted as previously described (Chen et al., 2021). Briefly, Serial 10-fold di-
lutions of 2B04 and 2H04 were incubated with 100 FFUs of SARS-CoV-2 variant strains for 1 hour at 37C. The antibody-virus com-
plexes were then added to Vero-hACE2-TMPRSS2 cell monolayers and incubated for 1 hour at 37C. The cells were then overlaid
with 1% w/v methylcellulose in MEM supplemented with 2% FBS. After 24 hours, overlays were removed and cells were fixed with
4%PFA in PBS for 20minutes at room temperature. Plates were washed and incubated with an oligoclonal pool of anti-SARS-CoV-2
spike antibodies followed by HRP-conjugated goat anti-mouse IgG (Sigma) in PBS with 0.1% saponin and 0.1% BSA. Plates were
developed with TrueBlue peroxidase substrate and quantified using an ImmunoSpot microanalyzer.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical methods were used to determine appropriate powering of experiments a priori. Details of statistical methods can be
found in figure legends associated with the experiment upon which statistical methods were applied.
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Figure S1: Cryo-EM validation for 2B04 and 2H04 maps. Related to figure 1. (A) Example micrographs and CTF 
estimates for 2B04-spike datasets imaged on holey lacey carbon grids or lacey carbon grids with ultra-thin carbon film. (B) 
Example micrographs and CTF estimates for 2H04-spike datasets imaged with holey lacey carbon grids or lacey carbon 
grids with ultra-thin carbon film. (C) Particle orientation distribution for 2B04-spike up/down/down reconstruction. (D) 
Particle orientation distribution for 2H04-spike down/down/down reconstruction. (E) GSFSC curve for 2B04-spike 
up/down/down refinement. (F) GSFSC curve for 2H04-spike down/down/down refinement. (G) Local resolution map for 
2B04-spike up/down/down map. (H) Local resolution map for 2H04-spike down/down/down map. 
Figure S2: Cryo-EM processing strategy. Related to figures 1 and 2. (A) Flowchart depicting cryo-EM data processing 
steps for the 2B04-spike up/down/down and 2B04/RBD locally refined maps. (B) Flowchart depicting cryo-EM data 
processing steps for the 2H04-spike down/down/down and 2H04/RBD locally refined maps.
Figure S3: Model fits into maps and validation for locally refined maps. Related to figures 1 and 2. (A) Density map 
for 2B04 U/D/D spike reconstruction shown as an outline, with the model shown internally as a cartoon. S1/S2 is depicted 
in green, with the RBD portion shown in yellow. 2B04 is shown in cyan. (B) Density map for 2B04 U/U/D spike 
reconstruction shown as an outline, with the model shown internally as a cartoon and colored as in A. (C) Density map for 
2H04 D/D/D spike reconstruction shown as an outline, with the model shown internally as a cartoon. S1/S2 is depicted in 
green, with the RBD portion shown in yellow. 2H04 is shown in magenta. (D) Density map for 2H04 U/D/D spike 
reconstruction shown as an outline, with the model shown internally as a cartoon and colored as in C. (E) GSFSC curve for 
the locally refined 2B04/RBD map. (F) GSFSC curve for the locally refined 2H04/RBD map. (G) Example density and 
model fits for an RBD beta-strand (left) and at the 2B04/RBD interface (right). RBD is colored in yellow, 2B04 heavy chain
is colored in cyan. (H) Example density and model fits for an RBD beta-strand (left) and at the 2H04/RBD interface (right). 
RBD is shown in yellow. 2H04 heavy chain is shown in magenta, while the light chain is shown in violet.
Figure S4: 2H04 contacts the core fucose of the N343 glycan on SARS-CoV-2 RBD. Related to figure 2. 2H04 is 
depicted as a surface, with the heavy chain colored magenta and the light chain colored violet. The N343 glycan is depicted 
as atoms in blue, with the remainder of the N-terminal strand of the RBD depicted in silver as a cartoon ribbon. Residues at 
the interface between the core fucose and 2H04 are labelled in black text.
Figure S5: Binding affinity of 2B04 and 2H04 to mammalian cell-derived SARS-CoV-2 RBD. Related to figure 6. (A) 
Binding of 2B04 to mammalian cell-derived SARS-CoV-2 RBD. (B) Binding of 2H04 to mammalian cell-derived SARS-
CoV-2 RBD. (C) Binding of 2H04 to bacterially derived SARS-CoV RBD. (D) Binding of 2B04 to bacterially derived 
SARS-CoV RBD. Kinetic values were fitted to a 1:1 Langmuir binding model (KD, kinetic). Steady-state analysis is  shown 
below kinetic plots (KD, equilibrium) with inset Scatchard plots. Data were analyzed using Biaevaluation 3.1 (GE 
Healthcare).One representative trace of two or three independent experiments is shown.
Figure S6: Neutralization profiles of 2B04 and 2H04 IgG versus Fab. Related to figure 6. Serial dilutions of 2B04 or
2H04 mAbs or  Fabs were pre-mixed with GFP expressing VSV-SARS-CoV-2 for  1 hour,  followed by addition of  the
mixture to Vero E6-TMPRSS2 cells. GFP+ infected cells were quantified by flow cytometry 8 hours post of infection. Data
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Figure S7: Comparison of 2B04 and 2H04 to germline Ig sequences. Related to figure 3. (A) Sequence alignment of 
2B04 VH to IgH2-9-1 (2B04 VH parent germline sequence) and IgHV3-53*02 (germline sequence of human antibodies 
targeting an overlapping RBM epitope). Residues are colored from black to white according to degree of conservation. 
2B04 contact residues on the SARS-CoV-2 RBD are shown as cyan triangles. (B) Sequence alignment of 2B04 VL to 
IgVL1*01 (2B04 VL parent germline sequence), colored as in A. (C) Sequence alignment of 2H04 VH to IgHV1-55*01 
(2H04 VH parent germline sequence). Residues are colored from black to white according to degree of conservation. 2H04 
contact residues on the SARS-CoV-2 RBD are shown as pink triangles. (D) Sequence alignment of 2H04 VL to IgKV5-
48*01, colored as in C.
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Table S1: Cryo-EM data collection, processing, refinement, and validation statistics. Related to Figures 1 and 2.
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Table S2. GISAID citations. Related to Figure 4.

